Content about Quetiapine

December 2, 2013

The Food and Drug Administration has approved a generic version of a drug for schizophrenia and bipolar disorder made by Jubilant Life Sciences, the Indian drug maker said.

NOIDA, India — The Food and Drug Administration has approved a generic version of a drug for schizophrenia and bipolar disorder made by Jubilant Life Sciences, the Indian drug maker said.

Jubilant announced the approval of quetiapine fumarate tablets in the 25-mg strength. The drug is a generic version of AstraZeneca's Seroquel.

Various versions of the drug have annual sales of about $59 million, according to IMS Health.

 

November 29, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

Watson to change brand in 2013
PARSIPPANY, N.J. — Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said. Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission in October, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.


November 29, 2012

In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


October 29, 2012

Par Pharmaceutical Cos. has bought rights to a generic version of a drug used to treat bipolar disorder and schizophrenia.

WOODCLIFF LAKE, N.J. – Par Pharmaceutical Cos. has bought rights to a generic version of a drug used to treat bipolar disorder and schizophrenia.

September 24, 2012

It wasn’t that long ago that the branded drug industry was seen as an unstoppable titan of American industry, churning out a steady stream of breakthrough therapies and blockbuster products. But a tsunami of expiring patents on such top selling drugs as Lipitor, Plavix and Seroquel, combined with a slowdown in research and development, flattened the growth curve in recent years and opened the door for the ascendancy of generic drugs.

It wasn’t that long ago that the branded drug industry was seen as an unstoppable titan of American industry, churning out a steady stream of breakthrough therapies and blockbuster products. But a tsunami of expiring patents on such top selling drugs as Lipitor, Plavix and Seroquel, combined with a slowdown in research and development, flattened the growth curve in recent years and opened the door for the ascendancy of generic drugs.

March 28, 2012

Three companies have launched generic versions of a psychiatric drug made by AstraZeneca following a court decision turning down the Anglo-Swedish drug maker's request for an injunction against the Food and Drug Administration's approval of the generics.

NEW YORK — Three companies have launched generic versions of a psychiatric drug made by AstraZeneca following a court decision turning down the Anglo-Swedish drug maker's request for an injunction against the Food and Drug Administration's approval of the generics.

Dr. Reddy's Labs, Teva and Mylan announced Wednesday the launch of their respective versions of quetiapine fumarate tablets, generic formulations of AstraZeneca's Seroquel, in strengths ranging from 25 mg to 400 mg.

March 26, 2012

A federal court has dismissed a case that drug maker AstraZeneca filed against regulators regarding a drug used to treat psychotic and bipolar disorders, the company said Monday.

NEW YORK — A federal court has dismissed a case that drug maker AstraZeneca filed against regulators regarding a drug used to treat psychotic and bipolar disorders, the company said Monday.

October 7, 2011

Anglo-Swedish drug maker AstraZeneca has settled patent infringement lawsuits that it filed against two companies that had sought to market generic versions of one of its drugs.

NEW YORK — Anglo-Swedish drug maker AstraZeneca has settled patent infringement lawsuits that it filed against two companies that had sought to market generic versions of one of its drugs.

The company settled with Handa Pharmaceuticals and also with Accord Healthcare and Intas Pharmaceuticals over two generic versions of the bipolar disorder and schizophrenia treatment Seroquel XR (quetiapine fumarate) extended-release tablets.

September 28, 2011

A new report from the Department of Health and Human Services' Agency for Healthcare Research and Quality found little evidence to support the use of atypical antipsychotic drugs for uses other than those for which they have official approval.

ROCKVILLE, Md. — A new report from the Department of Health and Human Services' Agency for Healthcare Research and Quality found little evidence to support the use of atypical antipsychotic drugs for uses other than those for which they have official approval.

April 4, 2011

Canadian drug maker Intellipharmaceutics International is seeking approval for a generic version of a treatment for mental disorders.

TORONTO — Canadian drug maker Intellipharmaceutics International is seeking approval for a generic version of a treatment for mental disorders.

Intellipharmaceutics announced Monday that it had filed an application with the Food and Drug Administration for quetiapine fumarate extended-release tablets, a generic version of AstraZeneca’s Seroquel XR.

February 10, 2011

This year’s upcoming $29 billion wave of margin-friendly generic pharmaceuticals will be as big a growth catalyst for supermarket pharmacies as it will be for their pureplay drug store cousins, Credit Suisse research analyst Ed Kelly stated in a note published Thursday.

NEW YORK — This year’s upcoming $29 billion wave of margin-friendly generic pharmaceuticals will be as big a growth catalyst for supermarket pharmacies as it will be for their pureplay drug store cousins, Credit Suisse research analyst Ed Kelly stated in a note published Thursday.

Conservative projection models place the generic impact at 3% to 5% accretive to 2012 earnings, he reported, given that the channel fills between 10% and 15% of all retail prescriptions.

October 13, 2010

AstraZeneca is launching a new campaign focused on depression, the Anglo-Swedish drug maker said Thursday....

WILMINGTON, Del. AstraZeneca is launching a new campaign focused on depression, the Anglo-Swedish drug maker said Thursday.

 

The campaign, “Take on Depression,” consists of a Facebook page and Twitter feed designed to provide information on bipolar depression and major depressive disorder.

 

 

August 10, 2010

The drug market for unipolar depression will get smaller over the next decade due to...

August 8, 2010

Anglo-Swedish drug maker AstraZeneca has settled 17,500 product liability cases involving one of its drugs,...

June 10, 2010

Health insurer Blue Cross Blue Shield of Texas alleged that drug maker Pfizer marketed its...

June 6, 2010

From sophisticated computer-generated animation to camera work worthy of Hollywood to celebrity endorsements, direct-to-consumer drug...

March 17, 2010

A state judge in New Jersey has ruled in favor of AstraZeneca in the case...

January 12, 2010

Despite a warning from the Food and Drug Administration, blood sugar and cholesterol monitoring of...